Financial News
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ARDX, SESN and SAVA
NEW YORK, NY / ACCESSWIRE / September 24, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Ardelyx, Inc. (NASDAQ:ARDX)
Class Period: August 6, 2020 - July 19, 2021
Lead Plaintiff Deadline: September 28, 2021
Throughout the class period, Ardelyx, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.
Learn about your recoverable losses in ARDX: https://www.kleinstocklaw.com/pslra-1/ardelyx-inc-loss-submission-form?id=19851&from=1
Sesen Bio, Inc. (NASDAQ:SESN)
Class Period: December 21, 2020 - August 17, 2021
Lead Plaintiff Deadline: October 18, 2021
During the class period, Sesen Bio, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in SESN: https://www.kleinstocklaw.com/pslra-1/sesen-bio-inc-loss-submission-form?id=19851&from=1
Cassava Sciences, Inc. (NASDAQ:SAVA)
Class Period: February 2, 2021 - August 24, 2021
Lead Plaintiff Deadline: October 26, 2021
Throughout the class period, Cassava Sciences, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.
Learn about your recoverable losses in SAVA: https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19851&from=1
![](https://www.accesswire.com/users/newswire/images/665471/Klein-Logos_CTA-Logo-3.png)
Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm
View source version on accesswire.com:
https://www.accesswire.com/665471/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-ARDX-SESN-and-SAVA
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.